- Generic name
- Palonosetron
- Strength
- .075 mg/1.5 ml
- Dosage form
- Injection
- Manufactured by
- Orion Pharma Ltd.
Palostar 0.075 Injection
About Palostar 0.075 .075 mg/1.5 ml Injection
Palostar 0.075.075 mg/1.5 ml is a injection product of Orion Pharma Ltd. that contains Palonosetron. It may also be used for nausea and vomiting that is not well controlled, and for nausea and vomiting after surgery.
There are 16 brands of Palonosetron listed in Bangladesh.
What is Palostar 0.075 .075 mg/1.5 ml Injection?
The injection Palostar 0.075 contains Palonosetron and is made by Orion Pharma Ltd. It is used to prevent and treat nausea and vomiting that can happen after chemotherapy, radiotherapy, or surgery. It is commonly given in connection with treatments such as chemotherapy or radiotherapy, and may also be used for nausea and vomiting after surgery. Ask your doctor or pharmacist if you are unsure about it.
Uses of Palostar 0.075
It may also be used for nausea and vomiting that is not well controlled, and for nausea and vomiting after surgery. It may be used for radiotherapy-related nausea as well. It is an anti-emetic, a medicine that acts against vomiting. Your doctor will decide if it is right for your situation.
How to use Palostar 0.075
If you have questions about your dose or schedule, ask your healthcare team. Palostar 0.075 is given as an injection by a healthcare professional. Do not inject it yourself unless a doctor has shown you how. Do not take extra injections to make up for a missed one. Do not change the dose or stop early without asking your doctor. Always follow the instructions of your doctor or nurse.
Side effects of Palostar 0.075
If you notice any side effect that worries you, or if it does not settle, tell your doctor or pharmacist. Not everyone who receives the injection will have these effects. Your healthcare team can advise on what to do and whether any further care is needed. Tell your doctor if these bother you or do not settle.
Safety and precautions
Store in a cool, dry place away from light. Before treatment, tell your doctor about all your medical conditions and medicines. Do not receive Palostar 0.075 if you are allergic to Palonosetron or any ingredient in the injection. Ask your doctor first if any of these apply to you.
Frequently asked questions
What does Palostar 0.075 treat?
It may also be used for nausea and vomiting that is not well controlled, and for nausea and vomiting after surgery. It may be used for radiotherapy-related nausea as well.
How is Palostar 0.075 used?
If you have questions about your dose or schedule, ask your healthcare team. Palostar 0.075 is given as an injection by a healthcare professional.
Can Palostar 0.075 cause side effects?
If you notice any side effect that worries you, or if it does not settle, tell your doctor or pharmacist. Not everyone who receives the injection will have these effects.
Who should be careful with Palostar 0.075?
Store in a cool, dry place away from light. Before treatment, tell your doctor about all your medical conditions and medicines.
Indications
- Acute and delayed nausea and vomiting
- Uncontrolled nausea and vomiting
- Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
- Delayed CINV resulting in on days later with certain types of chemotherapy ... Read more
- Acute and delayed nausea and vomiting
- Uncontrolled nausea and vomiting
- Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
- Delayed CINV resulting in on days later with certain types of chemotherapy
- Radiotherapy-induced nausea and vomiting (RINV)
- Post-operative & Post-discharge nausea and vomiting (PONV & PDNV).
Pharmacology
Pharmacokinetics: Palonosetron exhibits linear dose-proportional pharmacokinetics over the doserange 1-90 pg/kg in healthy subjects and in patients with cancer. In cancer patients receiving single intravenous doses of Palonosetron in this dose range, the mean maximum plasma concentration (Cmax) ranges from 0.89 to 336 ng/ml and the area under the plasma concentration-time curve from zero to infinity (AUCo-co) ranges from 13.8 to 957 ng.h/ml. Palonosetron has a volume of distribution of approximately 6.9-7.9 L/kg, with approximately 62% bound to plasma proteins. Approximately 50% of Palonosetron is metabolized into two inactive metabolites that exhibit <1% of the 5-HT3 receptor antagonist activity. Approximately 40% of the drug is metabolised via kidney, 50% by liver CYP2D6 (mainly), CYP3A4 and CYP1A2 isoenzymes. About 50% of the drug goes under metabolism. After a single intravenous dose, approximately 40% is excreted as unchanged drug in the urine after 144 hours. Total body clearance of Palonosetron is 160±35 ml/h/kg, and renal clearance is 66.5±18.2 ml/h/kg in healthy subjects. Palonosetron exhibits a longer half-life (40 hours) and has a greater 5-HT3 receptor binding affinity.
Dosage & Administration
Chemotherapy-induced nausea and vomiting: Adult tablet dosage: 0.5 mg administered approximately 1 hour prior to the start of chemotherapy. Adult IV dosage: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before the start of chemotherapy.
Radiotherapy-induced nausea and vomiting: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before each week of radiation fraction.
Post-operative nausea and vomiting: A single IV dose of 0.075 mg should be administered over 10 seconds immediately before induction of anesthesia.
Children dosage: (1 month to 17 years): A single IV dose at 20 mcg/kg body weight. Which maximum dose is 1.5 mg.
Interaction
Contraindications
Side Effects
Pregnancy & Lactation
Overdose Effects
Storage Conditions
Alternative brands of Palonosetron
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.